Synchron (formerly Smart Stent) completes a $10M Series A round to fund first-in-human trials

Synchron has recently completed a $10 million Series A round, which will fund a first-in-human trial of their Stentrode device. The implantable device is designed to give paralyzed patients direct brain control of communication aids, robotic limbs and exoskeletons.

The Stentrode was developed by Dr Nicholas Opie and Dr Thomas Oxley at the University of Melbourne, the Florey Institute of Neuroscience and Mental Health and the Royal Melbourne Hospital in Australia. The company, SmartStent, was spun out in 2012.
Nicholas and Thomas were finalists in the inaugural 2014 MTGT Competition, and have since progressed in leaps and bounds. STC is excited to have been a part of their journey, and we can’t wait to see what happens next!

Visit to stay up to date, and find out more.